Visual quantitative analysis of hot literature on interstitial lung diseases based on Web of Science database

Update:Dec. 05, 2020Total Views:522Total Downloads:209 DownloadMobile

Author: Zhi-Jun FAN 1 Jia-Hui LI 1 Qiao WANG 1 Jia-Ming CAO 1 Hui-Yuan LIU 1 Yue-Lin ZHANG 1 Ling-Yu FU 1, 2*

Affiliation: 1. Department of Clinical Epidemiology and Evidence-based Medicine, the First Affiliated Hospital of China Medical University, Shenyang 110001, China 2. Medical Record Management Center of the First Affiliated Hospital of China Medical University, Shenyang 110001, China

Keywords: Interstitial lung disease CiteSpace Bibliometrics Visualization analysis

DOI:10.12173/j.issn.1004-5511.2020.06.01

Reference:Fan ZJ, Li JH, Wang Q, Cao JM, Liu HY, Zhang YL, Fu LY. Visual quantitative analysis of hot literature on interstitial lung diseases based on Web of Science database[J]. Yixue Xinzhi Zazhi, 2020, 30(6): 408-414. DOI: 10.12173/j.issn.1004-5511.2020.06.01.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References
Abstract

Objective  To make a visual bibliometric analysis of the development trend of interstitial lung diseases and research hotspots in international fields, and to provide reference information for the development of interstitial lung diseases research in China. Methods Using Citespace 5.5 software and Web of Science database as data source, the year, country, journal and keywords of interstitial lung diseases published in recent ten years were analyzed visually. Results  A total of 6098 literatures were retrieved, and the number of articles published has gradually increased since 2011. The country with the largest number of articles published is the United States, the highest cited rate of journal is AM J RESP CRIT CARE, and the authors with the highest number of articles and citations are Toby M Maher and Raghu G, respectively. The research focus in this field are epidemiology, inflammation and pathogenesis, diagnosis and treatment. Conclusion The international attention and research level of interstitial lung disease are increasing recently. Exploring the research hotspot and development trend in this field can provide direction and basis for China to keep up with the international research trend of interstitial lung disease.

Full-text
  Please download the PDF version to read the full text: download
References

1.Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD[J]. Curr Opin Pulm Med, 2013, 19(5): 453-459. DOI: 10.1097/MCP.0b013e328363f48d.

2.Castelino FV, Dellaripa PF. Recent progress in systemic sclerosis-interstitial lung disease[J]. Curr Opin Rheumatol, 2018, 30(6): 570-575. DOI: 10.1097/BOR.0000000000000544. 

3.Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824. DOI: 10.1164/rccm.2009-040GL. 

4.Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history[J]. Respirology, 2016, 21(3): 427-37. Doi: 10.1111/resp.12683.

5.Chen C, Hu Z, Liu S, et al. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace[J]. Expert Opin Biol Ther, 2012, 12(5): 593-608. DOI: 10.1517/14712598.2012.674507. 

6.Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat[J]. Respir Res, 2019, 20(1): 205. DOI: 10.1186/s12931-019-1161-4.

7.Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial[J]. Lancet Respir Med, 2018, 6(8): 627-635.  DOI: 10.1016/S2213-2600(18)30181-4. 

8.Fletcher SV, Jones MG, Renzoni EA, et al. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice[J].  ERJ Open Res, 2018, 4(4): 00049-2018. DOI: 10.1183/23120541.00049-2018.

9.Distler O, Gahlemann M, Maher TM. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply[J]. N Engl J Med, 2019, 381(16): 1596-1597. DOI: 10.1056/NEJMc1910735.

10.Distler O, Volkmann ER, Hoffmann-Vold AM, et al. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease[J]. Expert Rev Clin Immunol, 2019, 15(10): 1009-1017. DOI: 10.1080/1744666X.2020.1668269.

11.Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2018, 198(5): e44-e68. DOI: 10.1164/rccm.201807-1255ST. 

12.Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22): 2071-2082. DOI: 10.1056/NEJMoa1402584. 

13.Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2013, 188(6): 733-748. DOI: 10.1164/rccm.201308-1483ST. 

14.Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases[J]. 1994, 150(4): 967-972. DOI: 10.1164/ajrccm.150.4.7921471. 

15.Jafri S, Ahmed N, Saifullah N, et al. Epidemiology and Clinico-radiological features of Interstitial Lung Diseases[J]. Pak J Med Sci, 2020, 36(3): 365-370. DOI: 10.12669/pjms.36.3.1046. 

16.Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study[J]. Am J Respir Crit Care Med, 2000, 161(1): 5-8. DOI: 10.1164/ajrccm.161.1.9906062.

17.Cameli P, Carleo A, Bergantini L, et al. Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis[J]. Inflammation, 2020, 43(1): 1-7. DOI: 10.1007/s10753-019-01059-1.

18.Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease[J]. Curr Opin Rheumatol, 2017, 29(3): 254-259. DOI: 10.1097/BOR.0000000000000380. 

19.Ohno Y, Koyama H, Yoshikawa T, et al. State-of-the-Art Imaging of the Lung for Connective Tissue Disease (CTD) [J].Curr Rheumatol Rep, 2015, 17(12): 69. DOI: 10.1007/s11926-015-0546-8. 

20.Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2015, 192(2): e3-19. DOI: 10.1164/rccm.201506-1063ST.

21.Vassallo R, Thomas CF. Advances in the treatment of rheumatic interstitial lung disease[J]. Curr Opin Rheumatol, 2004, 16(3): 186-191. DOI: 10.1097/00002281-200405000-00004. 

22.练巧燕, 徐鑫, 罗群, 等. 肺移植治疗间质性肺疾病的疗效及预后影响因素分析 [J]. 中国呼吸与危重监护杂志, 2019, 18(2): 32-37. DOI: 10.7507/1671-6205.201806019. [Lian QY, Xu X, Luo Q, et al. Lung transplantation for interstitial lung disease : benefits and prognostic factors[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 32-37.]

23.姜涛,赵俊玲.医学文献计量分析的研究现状探讨[J].河北医学, 2014, (12): 2141-2143. DOI: 10.3969/j.issn. 1006-6233.2014.12.091.[Jiang T, Zhao JL. Discussion on the research status of medical literature metrological analysis[J]. Hebei Medicine, 2014, (12): 2141-2143.]

Hot Papers